New combo therapy targets breast cancer brain metastases in early trial
NCT ID NCT07396454
First seen Feb 11, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study is for people with a type of breast cancer called HER2-negative that has spread to the brain. It tests whether adding a drug called anlotinib to standard radiation therapy can help control the cancer in the brain for longer. About 39 participants will receive this combination treatment. The goal is to see if the treatment is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.